CD8A and metabolic dysfunction-associated steatohepatitis: Despite the large availability of cancer CD8 T cells upon therapeutic PD-1 or PD-L1-related immunotherapy, no signs of NASH-driven HCC regression were observed, demonstrating that PD-1+ CD8 T cell-mediated tissue damage leads to HCC development (48).